Abstract
Female sexual dysfunction, a common, multifactorial, and often undertreated medical condition, attracted the attention of the medical community with the successful introduction of medical therapy for male erectile dysfunction. This review discusses the updated classification systems and definitions, epidemiologic aspects, and new pathophysiologic and therapeutic implications of this sexual disorder.
Similar content being viewed by others
References and Recommended Reading
Basson R, Berman J, Burnett A, et al.: Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol 2000, 163:888–893. This paper reports on the results from a multidisciplinary consensus conference that produced updated definitions and classifications of FSD.
Laumann EO, Paik A, Rosen RC: Sexual dysfunction in the United States: relevance and predictors. JAMA 1999, 281:537–544. A well-conducted, and still one of the most important epidemiologic studies on sexual dysfunction in the United States.
Berman JR, Goldstein I: Female sexual dysfunction. Urol Clin North Am 2001, 28:405–416.
Kaplan HS: The New Sex Therapy. New York: Brunner Mazel; 1974.
Masters WH, Johnson VE: Human Sexual Inadequacy. Boston: Little Brown; 1970.
Rosen RC: Prevalence and risk factors of sexual dysfunction in men and women. Curr Psychiatry Rep 2000, 2:189–195.
American Psychiatric Association: DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, edn. 4. Washington, DC: American Psychiatric Press; 1994.
World Health Organization: ICD 10: International Statistical Classification of Diseases and Related Health Problems. Geneva; World Health Organization: 1992.
Basson R: The female sexual response: a different model. J Sex Marital Ther 2000, 26:51–65.
Berman JR, Bassuk J: Physiology and pathophysiology of female sexual function and dysfunction. World J Urol 2002, 20:111–118.
Goldstein I, Berman JR: Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insufficiency syndromes. Int J Impot Res 1998, 10(Suppl 2):S84-S90.
Berman JR, Berman L, Goldstein I: Female sexual dysfunction: incidence, pathophysiology, evaluation, and treatment options. Urology 1999, 54:385–391.
Sipski ML, Rosen RC, Alexander CJ, et al.: Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injury. Urology 2000, 55:812–815.
Dundar M, Kocak I, Erkus M, et al.: The effect of estrogenreplacement therapy on clitoral-cavernosal tissue in oophorectomized rats: a histo-quantitative study by image analyzer. Urol Res 2001, 29:317–320.
Shafik A: The role of the levator ani muscle in evacuation, sexual performance and pelvic floor disorders. Int Urogynecol J Pelvic Floor Dysfunct 2000, 11:361–376.
Rosen RC, Lane RM, Menza M: Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999, 19:67–85.
Coleman CC, King BR, Bolden-Watson C, et al.: A placebocontrolled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 2001, 23:1040–1058.
Rosen RC, Leiblum SR: Treatment of sexual disorders in the 1990s: an integrated approach. J Consult Clin Psychol 1995, 63:877–890.
Burchardt M, Burchardt T, Anastasiadis AG, et al.: Sexual dysfunction is common and overlooked in female patients with hypertension. J Sex Marital Ther 2002, 28:17–26.
Stuart FM, Hammond DC, Pett MA: Inhibited sexual desire in women. Arch Sex Behav 1987, 16:91–106.
Dunn KM, Croft PR, Hackett GI: Sexual problems: a study of the prevalence and need for health care in the general population. Fam Pract 1998, 15:519–524.
Rosen RC, Taylor JF, Leiblum SR, et al.: Prevalence of sexual dysfunction in women: results of a survey study of 329 women in an outpatient gynecological clinic. J Sex Marital Ther 1993, 19:171–188.
Heimann JR, Grafton-Becker V: Orgasmic Disorders in Women. New York: Guidford Press; 1989.
Jamieson DJ, Steege JF: The prevalence of dysmenorrhea, dyspareunia, pelvic pain, and irritable bowel syndrome in primary care practices. Obstet Gynecol 1996, 87:55–58.
Shokrollahi P, Mirmohamadi M, Mehrabi F, et al.: Prevalence of sexual dysfunction in women seeking services at family planning centers in Tehran. J Sex Marital Ther 1999, 25:211–215.
Van Geelen JM, van de Weijer H, Arnolds H: Urogenital symptoms and their resulting discomfort in non-institutionalized 50-to-75-year-old Dutch women [in Dutch]. Ned Tijdschr Geneeskd 1996, 140:713–716.
Stenberg A, Heimer G, Ulmsten U: The prevalence of urogenital symptoms in postmenopausal women. Maturitas 1995, 22(Suppl):S17-S20.
Spector IP, Carey MP: Incidence and prevalence of the sexual dysfunctions: a critical review. Arch Sex Behav 1990, 19:389–409.
Leiblum SR, Wiegel M: Psychotherapeutic interventions for treating female sexual dysfunction. World J Urol 2002, 20:127–136. This article is an extremely well-written review about sex therapy for FSD from one of the experts in the field.
Burnett AL, Calvin DC, Silver RI, et al.: Immunohistochemical description of nitric oxide synthase isoforms in human clitoris. J Urol 1997, 158:75–78.
Palle C, Bredjkaer HE, Ottesen B, et al.: Vasoactive intestinal polypeptide and human vaginal blood flow: comparison between transvaginal and intravenous administration. Clin Exp Pharmacol Physiol 1990, 17:61–68.
Basson R: The complexities of female sexual arousal disorder: potential role of pharmacotherapy. World J Urol 2002, 20:119–126. This is an excellent update on pathophysiologic and therapeutic perspectives in FSD.
Sipski M, Rosen RC, Alexander CJ, et al.: Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injury. Urology 2000, 55:812–815.
Caruso S, Intelisano G, Lupo L, Agnello C: Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. BJOG 2001, 108:623–628.
Shen WW, Urosevich Z, Clayton DO: Sildenafil in the treatment of female sexual dysfunction induced by selective serotonin reuptake inhibitors. J Reprod Med 1999, 44:535–542.
Hoyle CHV, Stones RW, Robson T, et al.: Innervation of vasculature and microvasculature of the human vagina by NOS and neuropeptide-containing nerves. J Anat 1996, 188:633–644.
Davis SR: Androgens and female sexuality. J Gend Specif Med 2000, 3:36–40.
Davis SR, Tran J: Testosterone influences libido and well being in women. Trends Endocrinol Metab 2001, 12:33–37. This overview provides important information about the role of testosterone and androgen therapy for FSD, including presentation of currently available compounds, side effects, and results of new studies.
Shifren JL, Braunstein GD, Simon JA, et al.: Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000, 343:682–688.
Tuiten A, Van Honk J, Koppeschaar H, et al.: Time course and effects of testosterone administration on sexual arousal in women. Arch Gen Psychiatry 2000, 57:149–153.
Arlt W, Callies F, Van Vlijmen JC, et al.: Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999, 341:1013–1020.
Guay A, Davis SR: Testosterone insufficiency in women: fact or fiction? World J Urol 2002, 20:106–110. Another critical and important review of androgens and their role in FSD.
Billups KL: The role of mechanical devices in treating female sexual dysfunction and enhancing the female sexual response. World J Urol 2002, 20:137–141.
Hurlbert DF: The coital alignment technique and directed masturbation: a comparative study on female orgasm. J Sex Marital Ther 1995, 21:21–29.
Wilson SK, Delk JR 2nd, Billups KL: Treating symptoms of female sexual arousal disorder with the Eros-Clitoral Therapy Device. J Gend Specif Med 2001, 4:54–58.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Anastasiadis, A.G., Salomon, L., Ghafar, M.A. et al. Female sexual dysfunction: State of the art. Curr Urol Rep 3, 484–491 (2002). https://doi.org/10.1007/s11934-002-0102-8
Issue Date:
DOI: https://doi.org/10.1007/s11934-002-0102-8